Spine BioPharma

Spine BioPharma, established in 2015, is a clinical-stage biopharmaceutical company concentrating on non-surgical and non-opiate solutions for degenerative spine diseases. The company was founded by Marc R. Viscogliosi, who also serves as its Chairman and CEO. Mr. Viscogliosi has an extensive background in the medical technology industry, having co-founded Viscogliosi Brothers, LLC in 1999, a family office focused on musculoskeletal investments. His career includes experience as a Wall Street equity research analyst covering the neuro-musculoskeletal sector, and he has founded over 30 companies in the orthopedic field. This deep industry expertise directly informs Spine BioPharma's strategy.

The company is developing treatments for the millions of individuals suffering from chronic low back pain associated with Degenerative Disc Disease (DDD), a market affecting roughly 266 million people globally each year. The business operates in the biopharmaceutical sector, aiming to provide an alternative to invasive surgeries and opioid-based pain management. Revenue generation will be contingent upon the successful regulatory approval and commercialization of its therapeutic products. To date, the company has raised significant capital to fund its clinical trials and operations, with funding rounds totaling approximately $58.8 million from investors including Viscogliosi Bros., Pacira BioSciences, and Cercano Management.

Spine BioPharma's lead product candidate is SB-01 (also known as vicatertide), a first-in-class injectable therapeutic. SB-01 is a synthetic 7-amino acid peptide administered via a single intradiscal injection. Its mechanism of action involves modulating the activity of Transforming Growth Factor Beta 1 (TGF-β1), an inflammatory cytokine often overexpressed in degenerated spinal discs. By antagonizing TGF-β1, SB-01 aims to reduce inflammation and pain, and potentially slow the progression of the disease by promoting the production of the extracellular matrix that supports disc integrity. The company has completed enrollment for its Phase 3 clinical trial, known as the MODEL Study, to evaluate the safety and efficacy of SB-01. While the trial did not meet its primary endpoint due to a high sham control response at some sites, a notable percentage of patients receiving SB-01 showed clinically meaningful improvements in pain and function. The company has also expanded its rights to develop SB-01 for other indications like osteoarthritis and fibrotic diseases.

Keywords: Spine BioPharma, degenerative disc disease, chronic low back pain, non-surgical spine treatment, non-opioid pain relief, SB-01, vicatertide, intradiscal injection, Marc Viscogliosi, TGF-β1 inhibitor, clinical-stage biopharmaceutical, spine therapeutics, back pain injection, MODEL clinical trial, regenerative spine medicine, Viscogliosi Brothers, musculoskeletal investment, biopharma funding, spinal disease therapy, injectable peptide